S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

EWTX Edgewise Therapeutics Inc

33.00

0.80 (2.48%)

Nov 29 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

The sales under this filing are from Cashless Option Exercises that will occur within 3 months from the date of filings.

Date of Notice

02/07/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

03/30/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Behrad Derakhshan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Edgewise Therapeutics Charts.

Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Edgewise Therapeutics Charts.

Edgewise Therapeutics Inc News

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
Tuesday 26 November 2024 (5 days ago) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 7 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Thursday 7 November 2024 (3 weeks ago) • Business Wire

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
Tuesday 1 October 2024 (2 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 24 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 24 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 20 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 20 September 2024 (2 months ago) • Edgar (US Regulatory)

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
Thursday 19 September 2024 (2 months ago) • Business Wire

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
Tuesday 17 September 2024 (2 months ago) • Business Wire

More Edgewise Therapeutics Inc News Articles

Decentral Life (PK)

Digital Brand Media and ... (PK)

Northwest Biotherapeutics (QB)

Rennova Health (CE)

Kraig Biocraft Laborator... (QB)

Accredited Solutions (PK)

Bioelectronics (PK)

North Bay Resources (PK)

Lightwave Logic

Code Green Apparel (PK)

Fannie Mae (QB)

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions